First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy

Journal of Clinical Oncology

Volumn 16, Issue 7, 1998, Pages 2392-2400

  Silber, Jeffrey H ^a   Fridman, Moshe ^b   DiPaola, Robert S ^b   Erder, M Haim ^b   Pauly, Mark V ^b   Fox, Kevin R ^b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; METHOTREXATE;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; FEMALE; HEALTH CARE COST; HEMOGLOBIN DETERMINATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; NEUTROPENIA; NONBIOLOGICAL MODEL; ORAL DRUG ADMINISTRATION; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0031859789     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.7.2392     Document Type: Article

References (29)

1. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
2. Pizzo PA, Hathorn JW, Hiemenz J, et al: A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552-558, 1986
3. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
4. Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 315:164-170, 1991
5. Glaspy JA, Bleecker G, Crawford J, et al: The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer 29A:S23-30, 1993 (suppl 7)
6. Bodey GP, Buckley M, Sathe YS, et al: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328-340, 1966
7. Ohno R, Tomonaga M, Kobayashi T, et al: Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871-877, 1990
8. Gabrilove JL, Jakubowski A, Scher H, et al: Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-1422, 1988
9. Bronchud MH, Scarffe JH, Thatcher N, et al: Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 56:809-813, 1987
10. Brandt SJ, Peters WP, Atwater SK, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med 318:869-876, 1988
11. Antman KS, Griffin JD, Elias A, et al: Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med 319:593-598, 1988
12. Petros WP, Peters WP: Hematopoietic colony-stimulating factors and dose intensity. Semin Oncol 20:94-99, 1993
13. Molineux G, Xu C, Hendry J, et al: A cellular analysis of long-term hematopoietic damage in mice after repeated treatment with cyclophosphamide. Cancer Chemother Pharmacol 18:11-16, 1986
14. Nichols CR, Fox EP, Roth BJ, et al: Incidence of neutropenic fever in patients treated with standard-dose combination chemotherapy for small-cell lung cancer and the cost impact of treatment with granulocyte colony-stimulating factor. J Clin Oncol 12:1245-1250, 1994
15. Tancini G, Bonadonna G, Valagussa P, et al: Adjuvant CMF in breast cancer: Comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1:2-10, 1983
16. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each ± MER) for metastatic carcinoma of the breast: A CALGB study. J Clin Oncol 5:1523-1533, 1987
17. Ash A, Shwartz M: Evaluating the performance of risk-adjusted methods: Dichotomous outcomes, in Iezzoni LI (ed): Risk Adjustment for Measuring Healthcare Outcomes (ed 2). Chicago, IL, Health Administration, 1997, pp 432-443
18. Hellman S, Hannon E: Effects of Adriamycin on the radiation response of murine hematopoietic stem cells. Radiat Res 67:162-167, 1976
19. Abrams RA, Lichter AS, Bromer RH, et al: The hematopoietic toxicity of regional radiation therapy. Correlations of combined modality therapy with systemic chemotherapy. Cancer 55:1429-1435, 1985
20. Kleinbaum DG, Kupper LL, Muller KE: Applied Regression Analysis and Other Multivariable Methods (ed 2). Boston, MA, PWS-Kent, 1988, pp 271-274
21. Hosmer DW, Lemeshow S: Applied Logistic Regression. New York, NY, Wiley, 1989, pp 140-145
22. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
23. Hartmann LC, Tschetter LK, Habermann TM, et al: Granulocyte colony-stimulating factor in severe chemotherapy induced afebrile neutropenia. N Engl J Med 336:1776-1780, 1997
24. Hoelzer D: Hematopoietic growth factors - Not whether, but when and where. N Engl J Med 336:1882-1883, 1997
25. Gelber RD, Golhirsch A, Cavalli F: Quality of life adjusted evaluation of adjuvant therapies for operable breast cancer. Ann Intern Med 114:621-628, 1991
26. Gelber RD, Goldhirsch A, Coates AS: Adjuvant therapy for breast cancer: Understanding the overview. J Clin Oncol 11:580-585, 1993
27. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
28. Tannock IF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
29. Botnik LE, Hannon EC, Hellman S: A long-lasting proliferative defect in the hematopoetic stem cell compartment following cytotoxic agents. Int J Radiat Oncol Biol Phys 5:1621-1625, 1979